Nurix Therapeutics, Inc. (NRIX) Stock

Nurix Therapeutics, Inc. (NRIX) is a Healthcare stock trading at $26.71 (as of 2026-08-21), with a market capitalization of $2.77B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nurix Therapeutics, Inc. is a biopharmaceutical company that discovers, develops, and commercializes small-molecule therapies for cancer and immune disorders. Its pipeline includes BTK degraders (NX-2127 and NX-5948) and a CBL-B inhibitor for immuno-oncology (NX-1607), along with NX-0255 for ex vivo use in adoptive T-cell therapy and DeTIL-0255 for gynecologic cancers.

Understand Nurix Therapeutics, Inc.: how it makes money

Nurix Therapeutics develops small molecule cancer and immune disorder medicines, including oral BTK degraders and a CBL-B inhibitor, and makes money from licensing and collaboration arrangements, plus clinical milestone payments.

With no meaningful product sales indicated, the profit model is driven by monetizing its pipeline through licensing income and collaboration and clinical milestone payments, which are tied to clinical development progress.

Revenue by segment (latest quarter)
Lic.$0.0B
Clin. Mil.$0.0B
Collab.$0.0B

Business quality (Weak): Good directional clarity on revenue sources (license, clinical milestones, collaboration) and on clinical activity (response rates). Limitations include total revenue shown as 0.0B (rounding) and the absence of a large, clearly reported segment revenue base.

Bull case

  • Strong clinical response signal in CLL and SLL: Objective Response Rate (Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma) is 75.5 percent (and 84.2 percent at exploratory Week 16).
  • Pipeline is focused on oral targeted mechanisms in cancer and immune disorders: The company develops NX-2127 (oral BTK degrader), NX-5948 (oral BTK degrader), and NX-1607 (oral CBL-B inhibitor) for cancer and autoimmune diseases.

Bear case

  • Business economics remain severely unprofitable: Operating margin is -1479.4 for the period ended 2026-02-28.
  • Revenue mix suggests dependence on partnership monetization rather than product revenue: Reported revenue categories are small and are mainly licensing, clinical milestone, and collaboration revenue (0.03B, 0.01B, and 0.01B respectively).
Valuation — source: SEC EDGAR (first-party)
Price$26.71
Market Cap$2.77B
Price / Book6.88
Price / Sales94.15
FCF Yield-18.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$83.98M
Net Margin-314.9%
Revenue Growth (YoY)2.2%
EPS Growth (YoY)9.3%
FCF Growth (YoY)43.5%
Financial Health — source: SEC EDGAR
Altman Z-Score8.65 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($138.35M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOArthur T. Sands
Employees286
CountryUS
IPO Date2020-07-24

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Cytokinetics, Incorporated (CYTK)
  • Eton Pharmaceuticals, Inc. (ETON)
  • CytomX Therapeutics, Inc. (CTMX)
  • Lifecore Biomedical, Inc. (LFCR)
  • Assembly Biosciences, Inc. (ASMB)
  • Viridian Therapeutics, Inc. (VRDN)
  • Rockwell Medical, Inc. (RMTI)
NRIX earnings history · NRIX institutional & insider holders · NRIX KPIs & operating metrics · NRIX financials · NRIX investor presentations & press releases · NRIX SEC filings · NRIX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.